Pharma Market

Generics surge as patent expiry restores mkt pulse, boosting drug volumes

An analysis by Pharmarack, a market research firm, showed that 226 vildagliptin (anti-diabetic) brands are now available in the market after Novartis' patent expired in December 2019

Govt invites proposals for funding under Pharma MedTech sector scheme

The Department of Pharmaceuticals has sought expressions of interest from interested entities for project funding under the PRIP scheme. The Promotion of Research and Innovation in Pharma MedTech sector (PRIP) scheme has been launched by the Department of Pharmaceuticals to transform India into a global powerhouse for R&D in the Pharma MedTech sector. The scheme was notified on August 17, 2023, with a total financial outlay of Rs 5,000 crore, of which Rs 4,250 crore is focused on accelerating investments in the R&D ecosystem within the sector. Department of Pharmaceuticals invites Expressions of Interest (EoI) from interested entities --proprietary firm or partnership firm or limited liability partnership, startups or a company /Group of companies registered in India for project funding under the PRIP scheme, it stated. "This EoI has been designed to provide you with an opportunity to co-shape India's journey towards becoming an R&D innovation hub, by soliciting your ...

India's contract drug manufacturers seek govt support in China fight

"The government has to understand that this industry has potential, if not scale, right now," Krishna Kanumuri, CEO and managing director at Sai Life Sciences, said at an event earlier this week

Torrent Pharma Q2FY25 results: Net profit rises 17%, misses estimates

At an operational level, Torrent Pharma's earnings before interest, tax, depreciation, and amortisation stood at Rs 939 crore, with an Ebitda margin of 32.5 per cent

Indian pharmaceutical market registers over 6% growth in August 2024

Sheetal Sapale, vice-president (commercial) at Pharmarack, said that new introductions and price growth have driven the market growth for the month of August 2024

Biocon Biologics secures deal with Janssen to launch biosimilar Bmab 1200

Agreement clears way for Indian company to launch treatment in Europe, Canada and other markets

Aurobindo Pharma Q1FY25 results: Net profit jumps 61% to Rs 919 cr

Aurobindo Pharma on Saturday said its consolidated net profit increased 61 per cent year on year to Rs 919 crore in the first quarter ended June 2024, aided by strong sales across markets. The Hyderabad-based drug maker had reported a net profit of Rs 571 crore in the April-June quarter of last fiscal. Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement. "We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments," Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy stated. The profitability was sustained by improved gross margins and operational efficiencies, while ramping up our recently commercialised plants, he added. "We are confident in our ability to achieve our growth targets for FY25," Reddy said.

Govt notifies new marketing code for pharma cos to curb unethical practices

The Department of Pharmaceuticals on Tuesday notified a new code which prohibits pharma companies from offering gifts and travel facilities to healthcare professionals or their family members. The Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) 2024 also bans supply of free samples to those who are not qualified to prescribe such a product. "No gift should be offered or provided for personal benefit of any healthcare professional or family member (both immediate and extended) by any pharmaceutical company or its agent i.e. distributors, wholesalers, retailers, etc," as per the UCPMP guidelines. Similarly, no pecuniary advantage or benefit in kind may be offered, supplied, or promised to any person qualified to prescribe or supply drugs, by any pharmaceutical company or its agent i.e. distributors, wholesalers, retailers, etc, it added. Besides, the companies or their representatives, or any person acting on their behalf, should not extend travel facilities inside or ..

Dr Reddy's Lab Q3 results: PAT up 11%, beats estimates on strong US sales

The Hyderabad-based drug major had reported a net profit of Rs 1,247 crore for the October-December quarter of the last fiscal

Lupin gets USFDA nod to market generic hyperuricemia treatment drug

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator to market its generic Febuxostat tablets, indicated for the chronic management of hyperuricemia in adult patients with gout. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Febuxostat tablets of strengths 40 mg and 80 mg, a generic equivalent of Uloric tablets, 40 mg and 80 mg, of Takeda Pharmaceuticals USA, Inc, Lupin said in a regulatory filing. The product will be manufactured at the company's Pithampur facility in India, it added. The company said Febuxostat tablets of strengths 40 mg and 80 mg are indicated for the chronic management of hyperuricemia (elevated serum uric acid level) in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol; who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. Febuxostat tablets had estimated annual sales of U

Price push: Domestic pharma market grew by 6.8% in 2023, shows data

With an 8 percent growth in the anti-infectives category, it is not surprising that GlaxoSmithKline Pharmaceuticals (GSK) Augmentin is the top selling brand in 2023, second year in a row

Going viral: How is the pharma market coping with Janaushadhi Kendras?

Janaushadhi Kendras sell generic drugs that are priced 50 to 60 per cent lower than the popular brands

Pharma lobby bats for drug approvals in India to align with global markets

Launching a new drug in India takes up to four years longer than in markets such as the United States and the European Union, said the pharma lobby

Pharma industry needs to focus on innovative products, says Mandaviya

The domestic pharmaceutical industry needs to focus on the research and development of innovative products in order to move up the value chain and achieve global leadership in the sector, Union minister Mansukh Mandaviya said on Tuesday. The Union health minister, who also helms the Chemical and Fertilisers ministry, asked the medical technology companies to produce critical equipment in India for the global markets. While formally unveiling the National Policy on Research & Development and Innovation in the Pharma-Med Tech Sector here, Mandavya said the domestic pharmaceutical companies invest less on research and development when compared to multinational companies. "International MNCs spend 20-25 per cent of their profits in research and innovation while for Indian companies the average is around 10 per cent...Till the time we do not come out with research-led innovative products, we cannot lead the segment globally," he noted. He said the government wants to make the pharma ...

Herbal pharma demand highlights traditional practices value: Mandaviya

Union Health Minister Mansukh Mandaviya on Thursday pitched for collective efforts by embracing ancient wisdom and modern science to achieve the health-related sustainable development goals. Inaugurating the WHO's first-ever Global Summit for Traditional Medicine here, the minister said it presents a unique platform for dialogue, idea exchange, collaboration, and international partnerships in the realm of traditional and complementary medicine. World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, Union Ayush Minister Sarbananda Sonowal and Gujarat Chief Minister Bhupendrabhai Patel were present at the inaugural event. Co-hosted by the Ministry of Ayush, the summit is a co-branded event as part of the ongoing G20 Health Ministers' meeting being held in Gandhinagar in Gujarat from August 17 to 19. Mandaviya said, "For centuries, traditional and complementary medicine has played a pivotal role in promoting personal and community health. Even in modern times, th

Fierce competition among new drug brands for share of India market

The competitive intensity is high between brands, at a time when volume growth in the domestic pharma market is on a slow lane

India finds 'violations' at cough syrup maker linked to Cameroon deaths

Authorities have stepped up scrutiny of drugmakers after some cough syrups made in India were linked to deaths of dozens of children overseas

Indian pharma market back to pre-Covid level in FY23, says report

After a Covid-hit FY21 (when the IPM grew by only 2.2 per cent), the market posted a growth of 14.7 per cent in FY22, on a low base

Chintan shivir on drugs to diagnose and treat issues of trust, quality

Proposals to be discussed at Hyderabad conclave include having a centralised drug registration system under CDSCO

Pharma marketing practices: High-level committee to meet industry on Friday

The UCPMP is voluntary and there is no legal penalty for violating the code